The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis.

[1]  L. D. Del Priore,et al.  Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots. , 2007, American journal of ophthalmology.

[2]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[3]  Jennifer I. Lim.  MACULAR DEGENERATION: THE LATEST IN CURRENT MEDICAL MANAGEMENT , 2006, Retina.

[4]  D. Pauleikhoff,et al.  NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Natural History and Treatment Outcomes , 2005, Retina.

[5]  Sholom Wacholder,et al.  Case–Control Study , 2005 .

[6]  Sanjay Sharma,et al.  Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. , 2005, Canadian Journal of Ophthalmology-journal Canadien D Ophtalmologie.

[7]  J. Jonas,et al.  Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide. , 2005, American journal of ophthalmology.

[8]  E. Stefánsson,et al.  The time pattern of bilateral exudative age-related macular degeneration. , 2005, Acta ophthalmologica Scandinavica.

[9]  P. Tommila,et al.  Strontium plaque brachytherapy for exudative age-related macular degeneration: three-year results of a randomized study. , 2005, Ophthalmology.

[10]  W. Inhoffen,et al.  Natural course of occult choroidal neovascularization in age-related macular degeneration: development of classic lesions in fluorescein angiography. , 2005, Acta ophthalmologica Scandinavica.

[11]  J. Jonas,et al.  Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study , 2005, Eye.

[12]  Johanna M Seddon,et al.  Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. , 2003, Ophthalmology.

[13]  L. Singerman,et al.  Natural history of subfoveal pigment epithelial detachments associated with subfoveal or unidentifiable choroidal neovascularization complicating age-related macular degeneration , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[14]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[15]  David J. Wilson,et al.  Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. , 2004, Ophthalmology.

[16]  M. Maguire,et al.  The age-related macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study. , 2004, American journal of ophthalmology.

[17]  Matthew A. Thomas,et al.  Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. , 2004, Ophthalmology.

[18]  Prismatic correction in patients affected by age-related macular degeneration , 2004, Clinical rehabilitation.

[19]  Sanjay Sharma,et al.  Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration: results of an effectiveness study. , 2004, Archives of ophthalmology.

[20]  U. Schmidt-Erfurth,et al.  Effects of verteporfin therapy on central visual field function. , 2004, Ophthalmology.

[21]  P. Jong.  Prevalence of age-related macular degeneration in the United States. , 2004 .

[22]  N. Bressler,et al.  Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management--TAP report No. 6. , 2004, Archives of ophthalmology.

[23]  E. Steuer,et al.  Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. , 2004, Ophthalmology.

[24]  J. Jonas,et al.  Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. , 2004, Archives of ophthalmology.

[25]  G. Soubrane,et al.  Indirect scatter laser photocoagulation to subfoveal choroidal neovascularization in age-related macular degeneration , 1997, Graefe's Archive for Clinical and Experimental Ophthalmology.

[26]  M. Tsilimbaris,et al.  The Role of Lanreotide in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: A Pilot Clinical Trial , 2003, Retina.

[27]  G. Rubin,et al.  Visual acuity and contrast sensitivity in patients with neovascular age-related macular degeneration , 2003, Graefe's Archive for Clinical and Experimental Ophthalmology.

[28]  Michael Stur,et al.  Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. , 2003, American journal of ophthalmology.

[29]  Irene Barbazetto,et al.  Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. , 2003, Archives of ophthalmology.

[30]  U. Schmidt-Erfurth,et al.  Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. , 2003, Ophthalmology.

[31]  P. Mitchell,et al.  A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. , 2003, Archives of ophthalmology.

[32]  R. Danis,et al.  Proton therapy for exudative age-related macular degeneration: a randomized, sham-controlled clinical trial. , 2002, American journal of ophthalmology.

[33]  M. Blumenkranz,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. , 2002, Archives of ophthalmology.

[34]  R. Klein,et al.  Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. , 2002, Ophthalmology.

[35]  A. Bird,et al.  Visual prognosis of second eyes in patients with unilateral late exudative age-related macular degeneration , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

[36]  S. Harding.  Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials¿TAP Report No. 5 , 2002 .

[37]  Neil M Bressler,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. , 2002, American journal of ophthalmology.

[38]  A. Bird,et al.  Visual outcomes in the subfoveal radiotherapy study: a randomized controlled trial of teletherapy for age-related macular degeneration. , 2002, Archives of ophthalmology.

[39]  Simon P. Harding,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. , 2001, American journal of ophthalmology.

[40]  A Hofman,et al.  Risk factors for age-related macular degeneration: Pooled findings from three continents. , 2001, Ophthalmology.

[41]  J. Alexander,et al.  External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomized clinical trial. , 2001, Archives of ophthalmology.

[42]  N. Bressler,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.

[43]  George A. Williams,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. , 2001, Ophthalmology.

[44]  N. Vukojević,et al.  Brachytherapy--optional treatment for choroidal neovascularization secondary to age-related macular degeneration. , 2001, Collegium antropologicum.

[45]  Hiroshi Kobayashi,et al.  Age-related macular degeneration: long-term results of radiotherapy for subfoveal neovascular membranes. , 2000, American journal of ophthalmology.

[46]  Kanji Takahashi,et al.  The second eye of Japanese patients with unilateral exudative age related macular degeneration , 2000, The British journal of ophthalmology.

[47]  G. Calori,et al.  Indocyanine green angiography of well-defined plaque choroidal neovascularization in age-related macular degeneration. , 2000, Archives of ophthalmology.

[48]  M. Desantis,et al.  LASER TREATMENTS WITH VERTEPORFIN THERAPY AND ITS POTENTIAL IMPACT ON RETINAL PRACTICES , 2000, Retina.

[49]  T. Ciulla,et al.  INTRAVITREAL TRIAMCINOLONE ACETONIDE IN EXUDATIVE AGE‐RELATED MACULAR DEGENERATION , 2000, Retina.

[50]  J. Quivey,et al.  Randomized trial of radiation for age-related macular degeneration. , 1999, American journal of ophthalmology.

[51]  G. Soubrane,et al.  Natural History of Macular Subretinal Hemorrhage in Age-Related Macular Degeneration , 1999, Ophthalmologica.

[52]  A. Bird,et al.  Long-term drusen study. , 1999, Retina.

[53]  A. Deutman,et al.  A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation , 1998, Graefe's Archive for Clinical and Experimental Ophthalmology.

[54]  A Hofman,et al.  Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. , 1998, Archives of ophthalmology.

[55]  M. Sandberg,et al.  High-risk characteristics of fellow eyes of patients with unilateral neovascular age-related macular degeneration. , 1998, Ophthalmology.

[56]  Mark S. Blumenkranz,et al.  Laser treatment in eyes with large drusen. Short-term effects seen in a pilot randomized clinical trial. Choroidal Neovascularization Prevention Trial Research Group. , 1998, Ophthalmology.

[57]  J. Duker,et al.  Indocyanine green hyperfluorescence associated with serous retinal pigment epithelial detachment in age-related macular degeneration. , 1997, Ophthalmology.

[58]  M G Maguire,et al.  Occult choroidal neovascularization in age-related macular degeneration. A natural history study. , 1997, Archives of ophthalmology.

[59]  Judith Alexander,et al.  Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group. , 1997, Archives of ophthalmology.

[60]  N. Bressler,et al.  Macular scatter ('grid') laser treatment of poorly demarcated subfoveal choroidal neovascularization in age-related macular degeneration. Results of a randomized pilot trial. , 1996, Archives of ophthalmology.

[61]  D. Archer,et al.  Teletherapy for subfoveal choroidal neovascularisation of age-related macular degeneration: results of follow up in a non-randomised study. , 1996, The British journal of ophthalmology.

[62]  M. Stur,et al.  Oral zinc and the second eye in age-related macular degeneration. , 1996, Investigative ophthalmology & visual science.

[63]  Judith Alexander,et al.  Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Macular Photocoagulation Study Group. , 1996, Archives of ophthalmology.

[64]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[65]  R. Avery,et al.  Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. , 1996, Retina.

[66]  J. J. Wang,et al.  Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. , 1995, Ophthalmology.

[67]  Gordon E. Legge,et al.  Printed cards for measuring low-vision reading speed , 1995, Vision Research.

[68]  H. Lund‐Andersen,et al.  Interferon alfa-2a modifies the course of subfoveal and juxtafoveal choroidal neovascularisation. , 1994, The British journal of ophthalmology.

[69]  L. Atmaca,et al.  Natural progression of age-related macular degeneration. , 1993, Annals of ophthalmology.

[70]  O. Baun,et al.  Natural course in fellow eyes of patients with unilateral age‐related exudative maculopathy , 1993, Acta ophthalmologica.

[71]  A. Eisner,et al.  Visual function and the subsequent development of exudative age-related macular degeneration. , 1992, Investigative ophthalmology & visual science.

[72]  M. Uyama.  [Choroidal neovascularization, experimental and clinical study]. , 1991, Nippon Ganka Gakkai zasshi.

[73]  G Coscas,et al.  Perifoveal laser treatment for subfoveal choroidal new vessels in age-related macular degeneration. Results of a randomized clinical trial. , 1991 .

[74]  G Soubrane,et al.  Occult subretinal new vessels in age-related macular degeneration. Natural History and early laser treatment. , 1990, Ophthalmology.

[75]  J. Folk,et al.  Factors prognostic of visual outcome in patients with subretinal hemorrhage. , 1990, American journal of ophthalmology.

[76]  N. Bressler,et al.  Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. , 1990, Archives of ophthalmology.

[77]  A. Bird,et al.  The risk of fellow eye visual loss with unilateral retinal pigment epithelial tears. , 1989, American journal of ophthalmology.

[78]  R P Murphy,et al.  Natural course of poorly defined choroidal neovascularization associated with macular degeneration. , 1988, Archives of ophthalmology.

[79]  R. Murphy,et al.  Subfoveal choroidal neovascular membranes in age-related macular degeneration. Visual prognosis in eyes with relatively good initial visual acuity. , 1986 .

[80]  S. Fine,et al.  The second eye of patients with senile macular degeneration. , 1983, Archives of ophthalmology.

[81]  N. Bressler,et al.  SUBFOVEAL NEOVASCULAR MEMBRANES IN SENILE MACULAR DEGENERATION: Relationship Between Membrane Size and Visual Prognosis , 1983 .

[82]  London,et al.  Treatment of senile disciform macular degeneration: a single-blind randomised trial by argon laser photocoagulation. The Moorfields Macular Study Group. , 1982, The British journal of ophthalmology.

[83]  R P Murphy,et al.  Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. , 1982, American journal of ophthalmology.

[84]  Isaac Ben-Sira,et al.  TREATMENT OF NEOVASCULAR SENILE MACULOPATHY AT THE FOVEAL CAPILLARY FREE ZONE WITH RED KRYPTON LASER , 1982, Retina.

[85]  R S Nickerson,et al.  The Framingham Eye Study. I. Outline and major prevalence findings. , 1977, American journal of epidemiology.